RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an 'Outperform' rating for Arrowhead Pharma, maintaining a price target of $42.
September 26, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for Arrowhead Pharma, maintaining a price target of $42, indicating confidence in the company's future performance.
The reiteration of an 'Outperform' rating and a maintained price target of $42 by RBC Capital suggests a positive outlook for Arrowhead Pharma. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100